Eighty percent of the patients with FSGS progressed to end-stage renal disease during further follow-up Patients with FSGS had significantly lower levels of pSer473-Akt expression in PTEC in comparison to patients with MCD preceding progression as measured based on fluorescence intensity (Figure-6c,d). Here, AKT1 is linked to stage 5 chronic kidney disease.